US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

264.97

-5.9600-2.20%

Volume:71.47K

Turnover:18.95M

Market Cap:2.90B

PE:31.01

High:273.10

Open:273.10

Low:262.30

Close:270.93

52wk High:275.23

52wk Low:182.08

Shares:10.95M

Float Shares:10.95M

Volume Ratio:1.06

T/O Rate:0.65%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.04

PE(LYR):7.02

Loading ...

Overview Company News Filings

StemRIM Wins U.S. Patent for Stem Cell Gene Therapy Targeting Rare Skin Disease

NeoGenomics (NEO) Could Be 3% Overvalued After Guidance And CEO Change

Simply Wall St.

NeoGenomics on 'More Solid Footing' With Strong Revenue Growth, Needham Says

MT Newswires Live

NeoGenomics price target raised to $20 from $16 at StoneX

NeoGenomics Rises After BTIG Upgrades to 'buy'

Bruker Says timsTOF Mass Spectrometry Maps 179,000 Human Plasma Proteoforms in Draft Atlas

Untargeted Timstof Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

THOMSON REUTERS

BTIG Upgrades NeoGenomics to Buy From Neutral, Price Target is $28

MT Newswires Live

Neogenomics, Inc. : StoneX Raises Target Price to $20 from $16

THOMSON REUTERS

NeoGenomics Price Target Announced at $28.00/Share by BTIG

Cathie Wood’s ARK Investment buys 115.5K shares of Veracyte today

Corcept Endocrinology President Sean Maduck Disposes of USD 2.89 Million in Corcept Therapeutics Shares

Corcept Files Form 3 for President, Corcept Endocrinology Justin Gunn

Stocks to Watch: Standard BioTools, NeoGenomics, Pinterest

NeoGenomics down 2% at $18.73 after Q3 pre-announcement, CEO transition

NeoGenomics Expects to Increase FY Rev Guidance

NeoGenomics Lines up CEO Succession

NeoGenomics Names Warren Stone CEO Effective Jan. 4, 2027

Neogenomics, - Tony Zook to Become Executive Chairman Effective January 4, 2027

THOMSON REUTERS

Neogenomics, - Appoints Michael Kelly as Lead Independent Director Effective January 4, 2027

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/FBT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":264.97,"timestamp":1791316800000,"preClose":270.93,"halted":0,"volume":71469,"delay":0,"changeRate":-0.021998302144465284,"floatShares":10950002,"shares":10950002,"eps":8.545272,"marketStatus":"Pre-Mkt","change":-5.96,"latestTime":"10-07 04:00:02 EDT","open":273.1,"high":273.1,"low":262.3,"amount":18953471.5965,"amplitude":0.039863,"askPrice":271.25,"askSize":200,"bidPrice":262,"bidSize":200,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791379800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":264.97,"sharesOutstanding":11450002,"nav":270.76,"aum":2951284541.52,"bidAskSpread":0.001073,"postHourTrading":{"tag":"盘后","latestPrice":264.97,"preClose":264.97,"latestTime":"19:30 EDT","volume":23,"amount":6096.091,"timestamp":1791329403228,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.058095,"impliedVol":0.2498,"impliedVolPercentile":0.924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10950002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":1.0580946017177977,"shares":10950002,"dividePrice":0,"high":273.1,"amplitude":0.039863,"preClose":270.93,"low":262.3,"week52Low":182.08,"pbRate":"1.04","psRate":"699.94","week52High":275.23,"institutionHeld":0,"latestPrice":264.97,"eps":8.545272,"divideRate":0,"volume":71469,"delay":0,"ttmEps":8.545272,"open":273.1,"prevYearClose":206.52,"prevWeekClose":266.44,"prevMonthClose":272.26,"prevQuarterClose":272.26,"fiveDayClose":272.58,"twentyDayClose":265.78,"sixtyDayClose":247.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673937340","title":"StemRIM Wins U.S. Patent for Stem Cell Gene Therapy Targeting Rare Skin Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673937340","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673937340?lang=en_us&edition=fundamental","pubTime":"2026-10-07 14:55","pubTimestamp":1791356112,"startTime":"0","endTime":"0","summary":"StemRIM Inc. ( ($JP:4599) ) has shared an announcement. StemRIM Inc. has secured a U.S. patent for a stem cell gene therapy technology, development...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stemrim-wins-u-s-patent-for-stem-cell-gene-therapy-targeting-rare-skin-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stemrim-wins-u-s-patent-for-stem-cell-gene-therapy-targeting-rare-skin-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","IBB","TBXU","GNOM","USRD","SYNB","CNCR","BK4585","FBT","LFSC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673009501","title":"NeoGenomics (NEO) Could Be 3% Overvalued After Guidance And CEO Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2673009501","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673009501?lang=en_us&edition=fundamental","pubTime":"2026-10-07 13:25","pubTimestamp":1791350737,"startTime":"0","endTime":"0","summary":"NeoGenomics (NEO) has put investors on alert after issuing third quarter guidance that points to approximately US$209 million in revenue and about 28% NGS growth, alongside a planned CEO transition to Warren Stone.\nNeoGenomics has seen sharp swings around this guidance and leadership update, with the 1 day share price return down 13.72% and the 7 day share price return down 11.93%, even though the year to date share price return is 40.35% and the 1 year total shareholder return is 82.78%...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice1-card/1788942533039","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice1-card/1788942533039"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/neogenomics-neo-could-be-3-overvalued-after-guidance-and-ceo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/neogenomics-neo-could-be-3-overvalued-after-guidance-and-ceo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0012050646.USD","BK4121","BK4196","NEO","FBT","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068976","title":"NeoGenomics on 'More Solid Footing' With Strong Revenue Growth, Needham Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068976?lang=en_us&edition=fundamental","pubTime":"2026-10-07 02:42","pubTimestamp":1791312164,"startTime":"0","endTime":"0","summary":"NeoGenomics  is on \"more solid footing\" even after another change in the chief executive officer role, Needham said in a Tuesday note, citing revenue growth in next-generation sequencing and reimbursement wins for RaDaR MRD.Current Chief Operating Officer Warren Stone is set to become the company's fifth CEO in the past six years, as he succeeds current CEO Tony Zook on Jan. 4, Needham analysts said.Further, the analysts said they were \"encouraged\" by the company's above-consensus Q3 revenue guidance of about $209 million, including year-over-year next-generation sequencing revenue growth of around 28%.Needham reiterated the company's stock at buy and raised the price target to $22 from $19.Price: 16.70, Change: -2.43, Percent Change: -12.71","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FBT","BK4196","NEO","LU0106261612.USD","LU0012050646.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673052082","title":"NeoGenomics price target raised to $20 from $16 at StoneX","url":"https://stock-news.laohu8.com/highlight/detail?id=2673052082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673052082?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:05","pubTimestamp":1791299131,"startTime":"0","endTime":"0","summary":"StoneX analyst Bruce Jackson raised the firm’s price target on NeoGenomics (NEO) to $20 from $16 and keeps a Buy rating on the shares following the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neogenomics-price-target-raised-to-20-from-16-at-stonex-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neogenomics-price-target-raised-to-20-from-16-at-stonex-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","BK4121","LU0106261612.USD","BK4196","NEO","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056485","title":"NeoGenomics Rises After BTIG Upgrades to 'buy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056485?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:13","pubTimestamp":1791288838,"startTime":"0","endTime":"0","summary":"BUZZ-NeoGenomics rises after BTIG upgrades to 'buy'** Cancer diagnostics co NeoGenomicsNEO.Oshares rise more than 4% to $19.92 in premarket trading** BTIG raises rating to \"buy\" from \"neutral\"; PT at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4N45S0TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","BK4196","NEO","LU0106261612.USD","LU0012050646.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673053218","title":"Bruker Says timsTOF Mass Spectrometry Maps 179,000 Human Plasma Proteoforms in Draft Atlas","url":"https://stock-news.laohu8.com/highlight/detail?id=2673053218","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673053218?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:02","pubTimestamp":1791284567,"startTime":"0","endTime":"0","summary":"Bruker says timsTOF mass spectrometry maps 179,000 human plasma proteoforms in draft atlasBruker highlighted a bioRxiv preprint describing a draft human plasma proteome atlas mapped at proteoform reso","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDLbRxGWc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRKR","TINY","BK4121","FBT","LU0757428866.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673205343","title":"Untargeted Timstof Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution","url":"https://stock-news.laohu8.com/highlight/detail?id=2673205343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673205343?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:00","pubTimestamp":1791284401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA1FGS6J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TINY","BK4121","LU1815336091.USD","BRKR","FBT","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673580350","title":"BTIG Upgrades NeoGenomics to Buy From Neutral, Price Target is $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2673580350","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673580350?lang=en_us&edition=fundamental","pubTime":"2026-10-06 18:34","pubTimestamp":1791282845,"startTime":"0","endTime":"0","summary":"NeoGenomics (NEO) has an average rating of overweight and mean price target of $20.55, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FBT","BK4121","BK4196","LU0106261612.USD","NEO","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673605895","title":"Neogenomics, Inc. : StoneX Raises Target Price to $20 from $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2673605895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673605895?lang=en_us&edition=fundamental","pubTime":"2026-10-06 18:18","pubTimestamp":1791281916,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45S0O3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0012050646.USD","FBT","BK4196","LU0106261612.USD","NEO","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673586640","title":"NeoGenomics Price Target Announced at $28.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2673586640","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673586640?lang=en_us&edition=fundamental","pubTime":"2026-10-06 18:13","pubTimestamp":1791281580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NEO/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU0012050646.USD","FBT","NEO","LU0106261612.USD","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673080413","title":"Cathie Wood’s ARK Investment buys 115.5K shares of Veracyte today","url":"https://stock-news.laohu8.com/highlight/detail?id=2673080413","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673080413?lang=en_us&edition=fundamental","pubTime":"2026-10-06 08:25","pubTimestamp":1791246314,"startTime":"0","endTime":"0","summary":"20:23 EDT Cathie Wood’s ARK Investment buys 115.5K shares of Veracyte (VCYT) today Published first on TheFly – the ultimate source for real-time, m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-115-5k-shares-of-veracyte-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-115-5k-shares-of-veracyte-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKX","ARKK","FBT","VCYT","ARKF","BK4544","ARKQ","BK4139","ARKW","BK4585","ARKG","BK4588","SARK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673808390","title":"Corcept Endocrinology President Sean Maduck Disposes of USD 2.89 Million in Corcept Therapeutics Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673808390","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673808390?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:50","pubTimestamp":1791244214,"startTime":"0","endTime":"0","summary":"Corcept Endocrinology President Sean Maduck disposes of USD 2.89 million in Corcept Therapeutics sharesSean Maduck, President, Corcept Endocrinology, reported option exercises and share sales in Corce","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL7Q9kfn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck Disposes of USD 2.89 Million in Corcept Therapeutics Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","CORT","LU0566484027.USD","LU1559883803.SGD","BK4007","PSCH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673308745","title":"Corcept Files Form 3 for President, Corcept Endocrinology Justin Gunn","url":"https://stock-news.laohu8.com/highlight/detail?id=2673308745","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673308745?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:18","pubTimestamp":1791242335,"startTime":"0","endTime":"0","summary":"Corcept files Form 3 for President, Corcept Endocrinology Justin GunnCorcept’s President, Corcept Endocrinology Justin Frederick Gunn filed a Form 3 showing 12,191 shares of common stock.Disclosure al","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL83wYZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","FBT","LU1559883803.SGD","BK4532","LU0566484027.USD","BK4007","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673087968","title":"Stocks to Watch: Standard BioTools, NeoGenomics, Pinterest","url":"https://stock-news.laohu8.com/highlight/detail?id=2673087968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673087968?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:00","pubTimestamp":1791241200,"startTime":"0","endTime":"0","summary":"Standard BioTools agreed to sell its Microfluidics business to the investment firm Archimed. Shares gained 3% to $0.79 after the bell on Monday.NeoGenomics said it expects to raise its full-year guidance and appointed Chief Operating Officer Warren Stone as chief executive, effective Jan. 4, succeeding Tony Zook. Shares fell 3.6% to $18.45 after hours.Pinterest named James Dibbo, a former Amazon executive, as its next chief financial officer. The stock was up 1% at $20.25.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PINS","FBT","BK4551","BK4548","IE00B894F039.SGD","GB00BDT5M118.USD","IE00B19Z9P08.USD","BK4508","BK4196","BK4585","BK4534","LU0012050646.USD","IE00BZ9MQY76.HKD","BK4588","BK4121","IE00B19Z9Z06.USD","SMP","LU0348723411.USD","LU2317271919.USD","BK4077","BK4124","NEO","LAB","LU0106261612.USD","SOCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673084767","title":"NeoGenomics down 2% at $18.73 after Q3 pre-announcement, CEO transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2673084767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673084767?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:45","pubTimestamp":1791233110,"startTime":"0","endTime":"0","summary":"16:44 EDT NeoGenomics (NEO) down 2% at $18.73 after Q3 pre-announcement, CEO transition Published first on TheFly – the ultimate source for real-ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neogenomics-down-2-at-18-73-after-q3-pre-announcement-ceo-transition-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neogenomics-down-2-at-18-73-after-q3-pre-announcement-ceo-transition-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106261612.USD","LU0012050646.USD","BK4121","NEO","BK4196","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673084824","title":"NeoGenomics Expects to Increase FY Rev Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2673084824","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673084824?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:24","pubTimestamp":1791231840,"startTime":"0","endTime":"0","summary":"NeoGenomics expects 3Q revenue of about $209 million, with next-generation sequencing revenue up roughly 28% year over year. The company says the preliminary figure is expected to lead to an increase in full-year revenue guidance at the midpoint, with details to come on the earnings call. The company also reiterated its full-year adjusted Ebitda guidance. NeoGenomics announced its guidance as the oncology diagnostic company named Warren Stone as incoming CEO.This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NeoGenomics Expects to Increase FY Rev Guidance","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261612.USD","BK4121","LU0012050646.USD","FBT","BK4196","NEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673084835","title":"NeoGenomics Lines up CEO Succession","url":"https://stock-news.laohu8.com/highlight/detail?id=2673084835","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673084835?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:19","pubTimestamp":1791231540,"startTime":"0","endTime":"0","summary":"NeoGenomics names Warren Stone, its current president and COO, as incoming CEO, effective Jan. 4, 2027. Current CEO Tony Zook will shift to executive chairman the same day. The move follows years of internal planning, the company says, and emphasizes continuity in strategy. Stone joined NeoGenomics in 2022 and has held leadership roles including president of clinical services. Zook says the two will work closely through the transition and continue collaborating afterward.This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0012050646.USD","FBT","BK4196","LU0106261612.USD","BK4121","NEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081224","title":"NeoGenomics Names Warren Stone CEO Effective Jan. 4, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081224","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081224?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:07","pubTimestamp":1791230828,"startTime":"0","endTime":"0","summary":"NeoGenomics names Warren Stone CEO effective Jan. 4, 2027NeoGenomics named President and COO Warren Stone as CEO and a board member, effective Jan. 4, 2027.Stone, 54, previously held senior roles at O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDLrxfDk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0012050646.USD","BK4121","FBT","LU0106261612.USD","BK4196","NEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673608140","title":"Neogenomics, - Tony Zook to Become Executive Chairman Effective January 4, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673608140","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673608140?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:05","pubTimestamp":1791230701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA1SFY57:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BK4196","LU0012050646.USD","NEO","LU0106261612.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673108142","title":"Neogenomics, - Appoints Michael Kelly as Lead Independent Director Effective January 4, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673108142","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673108142?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:05","pubTimestamp":1791230701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA1SFY57:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","LU0012050646.USD","NEO","LU0106261612.USD","BK4121","BK4196"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}